



PRESS RELEASE

November 8, 2023

Ziccum CEO Analyst video interview: new industry Agreement, Q3 highlights

Watch Ziccum CEO Ann Gidner in an exclusive new video interview with Eucaps analyst Jonathan Furelid. It provides insights and analysis of Ziccum's new Evaluation Agreement, its third in six months, plus the company's Q3 highlights.

Watch the interview [HERE](#).

Or visit Ziccum's company page on Eucaps [HERE](#).

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is Erik Penser Bank AB
Follow us on <https://eucaps.com/ziccum>

About Ziccum

Ziccum is developing LaminarPace™, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

[Ziccum CEO Analyst video interview: new industry Agreement, Q3 highlights](#)